低剂量质氨酸在TAVI期间减少出血并发症的有效性和安全性:倾向匹配的比较
Kinan Kneizeh1, Andrea Milzi1, Felix Vogt1
1Department of Cardiology, Angiology and Critical Care (Medical Clinic 1), University Hospital RWTH Aachen, 52074 Aachen, Germany.
Journal of clinical medicine
|July 14, 2023
概括
低剂量质氨酸增加了通过导管大动脉植入术 (TAVI) 后的主要不良事件. 全剂量蛋白胺与更好的安全结果有关,减少了诸如出血和血管问题等并发症.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管外科 血管外科
背景情况:
- 接入部位的并发症对过导管大动脉植入 (TAVI) 的结果至关重要.
- 有限的数据存在于对TAVI患者肝素逆转的最佳蛋白胺剂量.
研究的目的:
- 为了比较低剂量与全剂量前胺的疗效和安全性.
- 评估TAVI程序中对访问场所相关并发症的影响.
主要方法:
- 对897名接受TAVI治疗的患者进行了回顾性分析.
- 第1组:近期PCI患者的低剂量质氨酸 (0.5毫克/100单位肝素).
- 第2组 (对照组):对所有其他患者,全剂量前胺 (1毫克/100单位肝素).
主要成果:
- 低剂量蛋白胺组的医院内结合终点 (死亡,严重出血,血管并发症) 显着更高.
- 倾向匹配证实了低剂量质氨酸作为不良事件的预测因素 (OR 3.54).
- 多变量分析确定了低剂量蛋白质胺和基线血红蛋白作为结合终点的预测因素.
结论:
- 低剂量质氨酸与TAVI后主要不良事件的增加有关.
- 全剂量蛋白质胺似乎更安全,减少了TAVI输血的并发症.
- 研究结果表明,在TAVI患者中,要仔细考虑蛋白质胺剂量.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
566
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
566


